DT7 peptide-modified lecithin nanoparticles co-loaded with γ-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity
Open Access
- 28 February 2022
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 533, 215608
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemiaBlood Reviews, 2011
- Glucocorticoid use in acute lymphoblastic leukaemiaThe Lancet Oncology, 2010
- Crosstalk in Inflammation: The Interplay of Glucocorticoid Receptor-Based Mechanisms and Kinases and PhosphatasesEndocrine Reviews, 2009
- Levels of glucocorticoid receptor and its ligand determine sensitivity and kinetics of glucocorticoid-induced leukemia apoptosisLeukemia, 2009
- γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemiaNature Medicine, 2008
- BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemiaBlood, 2008
- Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2EMBO Reports, 2008
- Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemiaNature Medicine, 2007
- Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemiaBlood, 2006
- Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic LeukemiaScience, 2004